Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 5 clients • 9 examiners • 9 art units • 0 of 11 (0%) have an AI response strategy ready
EpiMED LLC has managed 156 career applications within the Biotechnology & Pharmaceuticals sector. The firm has reached a resolved allowance rate of 56.06 percent, which defines its historical success rate in this technical field. This figure provides a baseline for understanding the firm's prosecution outcomes in biotechnology matters.
The firm averages 3.46 office actions per allowance during the prosecution process. Currently, EpiMED LLC is addressing 8 pending office actions, continuing its work in Biotechnology & Pharmaceuticals following its 156 career applications. This data provides a clear view of the firm's historical performance and current workload for practitioners assessing its prosecution history and administrative engagement.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (9%) |
| §112 only | 2 (18%) |
| Double-patenting + other | 3 (27%) |
| Multi-statute (no §101) | 5 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 2 | 57.0% | +19.9% |
| DRISCOLL, MAUREEN VARINA | 2 | 63.7% | +40.8% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.0% | +62.1% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| PATEL, SAGAR S | 1 | 75.7% | +34.6% |
| SAOUD, CHRISTINE J | 1 | 58.0% | +37.2% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| ESSEX, LAURA ANN | 1 | 60.5% | +35.2% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | DRISCOLL, MAUREEN VARINA | 259d overdue |
| 17909358 | GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF | DRISCOLL, MAUREEN VARINA | 168d overdue |
| 18039272 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | HOERNER, PAUL ELLSWORTH | — |
| 18030754 | Camptothecin Derivative And Ligand-drug Conjugate Thereof | ALDARONDO, DASIA ALI | — |
| 18008798 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | ESSEX, LAURA ANN | — |
| 16760466 | BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | AEDER, SEAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | DRISCOLL, MAUREEN VARINA | 259d overdue |
| 17909358 | GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF | DRISCOLL, MAUREEN VARINA | 168d overdue |
| 18030757 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | PATEL, SAGAR S | 72d overdue |
| 17909360 | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | KELLY, ROBERT M | 33d |
| 18693507 | METHODS OF TREATING CANCER AND THE PHARMACEUTICAL COMPOSITIONS THEREOF | AEDER, SEAN E | — |
| 18039272 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | HOERNER, PAUL ELLSWORTH | — |
| 18029043 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | SAOUD, CHRISTINE J | — |
| 18027583 | EGFR BINDING COMPLEX AND METHOD OF MAKING AND USING THEREOF | BRISTOL, LYNN ANNE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Baili-Bio (Chengdu) Pharmaceutical | 7 |
| Systimmune, Inc. | 1 |
| Seattle Gummy Company | 1 |
| Sichuan Baili Pharm Co., Ltd. | 1 |
| Sichuan Baili Pharmaceutical Co. Ltd. | 1 |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1611 | 1 |
| 1625 | 1 |
| 1626 | 1 |
| 1645 | 1 |
| 1643 | 1 |
| 1675 | 1 |
| 1638 | 1 |
| 1642 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18693507 | METHODS OF TREATING CANCER AND THE PHARMACEUTICAL COMPOSITIONS THEREOF | Systimmune, Inc. | AEDER, SEAN E | §102§103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 | |
| 18039272 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | Seattle Gummy Company | HOERNER, PAUL ELLSWORTH | 1611 | §103§112 | Non-Final OA | — | Pending | May 29, 2023 |
| 18030754 | Camptothecin Derivative And Ligand-drug Conjugate Thereof | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | ALDARONDO, DASIA ALI | 1625 | §103 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18030757 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | PATEL, SAGAR S | 1626 | §103§112DP | Final Rejection | 72d overdue | Pending | Apr 06, 2023 |
| 18029043 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | SAOUD, CHRISTINE J | 1645 | §102§103§112DP | Non-Final OA | — | Pending | Mar 28, 2023 |
| 18027583 | EGFR BINDING COMPLEX AND METHOD OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | BRISTOL, LYNN ANNE | 1643 | §112 | Final Rejection | — | Pending | Mar 21, 2023 |
| 18008798 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | Sichuan Baili Pharm Co., Ltd. | ESSEX, LAURA ANN | 1675 | §102§103§112 | Non-Final OA | — | Pending | Dec 07, 2022 |
| 17909360 | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | KELLY, ROBERT M | 1638 | §112 | Non-Final OA | 33d | Pending | Sep 03, 2022 |
| 17909358 | GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | DRISCOLL, MAUREEN VARINA | 1644 | §103§112Other | Non-Final OA | 168d overdue | Pending | Sep 02, 2022 |
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | DRISCOLL, MAUREEN VARINA | 1644 | §103§112Other | Non-Final OA | 259d overdue | Pending | Apr 29, 2022 |
| 16760466 | BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | Sichuan Baili Pharmaceutical Co. Ltd. | AEDER, SEAN E | 1642 | §103§112 | Non-Final OA | — | Pending | Apr 30, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial